Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment
Open Access
- 16 November 2024
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (1) , 193-210
Abstract
Introduction Factors influencing attention-deficit/hyperactivity disorder (ADHD) treatment preferences have been studied among patients but not physicians in the United States (US) and Canada. This study assessed treatment preferences of physicians treating adult patients with ADHD in both countries. Methods An online discrete choice experiment (DCE) was conducted (October 4–20, 2023) among physicians from Dynata’s US and Canadian panel who treated adult patients with ADHD. Preference weights for efficacy (improvement in ADHD symptoms) and safety [risks of adverse events (AEs)] attributes were estimated using a conditional logistic regression model, and were used to calculate the willingness to trade-off and relative importance of the attributes. Results Among 510 US and 347 Canadian physicians (64.1% and 69.2% male, respectively), improvement in ADHD symptoms had a significant positive impact, and the risks of AEs (except the risk of feeling jittery in Canada) had a significant negative impact on physician preferences for ADHD treatments. US physicians were willing to tradeoff 0.44, 0.35, 0.20, 0.17, and 0.17 percentage points of improvement in ADHD symptoms to avoid a one-percentage-point risk of insomnia, nausea, feeling jittery, anxiety, and dry mouth, respectively; among Canadian physicians, these were 0.31, 0.21, 0.12, 0.20, and 0.07, respectively. The relative importance of the efficacy versus safety attributes (i.e., the risks of AEs included in the DCE taken together) was 45.5% versus 54.5% in the US and 56.3% versus 43.7% in Canada. Conclusion Efficacy was the most important single attribute for physicians treating adult patients with ADHD in both the US and Canada; however, the risks of AEs taken together had greater relative importance than efficacy alone among US but not Canadian physicians. These findings highlight potential discrepancies in physician and patient preferences based on existing evidence and underscore the importance of shared decision-making, which may in turn increase patients’ treatment satisfaction.Keywords
Funding Information
- Otsuka Pharmaceutical Development and Commercialization
This publication has 34 references indexed in Scilit:
- Is Adult ADHD a Childhood-Onset Neurodevelopmental Disorder? Evidence From a Four-Decade Longitudinal Cohort StudyAmerican Journal of Psychiatry, 2015
- Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature reviewNeuropsychiatric Disease and Treatment, 2014
- Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East AsiaPatient Preference and Adherence, 2013
- The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic ReviewNeurotherapeutics, 2012
- Conjoint Analysis Applications in Health – How are Studies being Designed and Reported?The Patient - Patient-Centered Outcomes Research, 2010
- Medication Adherence in the MTA: Saliva Methylphenidate Samples Versus Parent Report and Mediating Effect of Concomitant Behavioral TreatmentJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysisThe British Journal of Psychiatry, 2009
- Once-Daily Atomoxetine for Adult Attention-Deficit/Hyperactivity DisorderJournal of Clinical Psychopharmacology, 2009
- Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity DisorderThe Journal of Clinical Psychiatry, 2008
- Stimulant Treatment Patterns and Compliance in Children and Adults With Newly Treated Attention-Deficit/Hyperactivity DisorderJournal of Managed Care Pharmacy, 2004